Several FGFR2 tyrosine kinase inhibitors (TKIs), including AZD4547 (NCT01457846, SHINE trial), dovitinib (NCT01719549), E7090 (NCT02275910), and TAS-120 (NCT02052778), have been evaluated for patients of gastric cancer with FGFR2 amplification16,40,41,53. This evidence concerns the gene FGFR2 and gastric cancer.